AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAY 5 - (NewsRx.com & NewsRx.net) -- A LTK63 mucosal adjuvant and the trimethyl chitosan delivery system allow the reduction of components that induce antibody responses to the CRM-MenC conjugate vaccine.
"Previous work had shown that the immunogenicity of conjugate vaccine against group C meningococci (CRM-MenC) is enhanced when it is delivered intranasally (inl) with mucosal adjuvants, such as mutants of the Escherichia coli enterotoxin (LT), and with delivery systems such as chitosan derivatives," scientists writing in the Journal of Infectious Diseases report.
"We show, in mice, that the concomitant use of limiting doses of the fully nontoxic LTK63 mutant as a mucosal adjuvant and of the trimethyl derivative of chitosan as a delivery system allows the reduction of each of the components for the induction of antibody and bactericidal responses to CRM-MenC conjugate vaccine delivered inl at titers similar to or higher than those induced by parenteral immunization," stated Barbara C. Baudner and collaborators at Chiron Srl in Italy and the Leiden/Amsterdam Center for Drug Research in the ...